Clinical Trials Browser

Phase 2/3 × INDUSTRY × catumaxomab × Clear all

NCT00836654 2009-02-05

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Phase 2/3 Completed

BreastGastrointestinalGynecologic

EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)